Parker Waichman LLP Headlines by Topic
Vytorin
Vytorin, Zetia Disappoint Again
Nov 16, 2009
| Parker Waichman LLP
Vytorin and Zetia, Merck & Co.'s anti-cholesterol medications, are coming under fire again. A new study has found that a much older - and...
Lawsuit Claims Execs Knew Vytorin Study Wouldn't Be Favorable
Oct 15, 2009
| Parker Waichman LLP
A lawsuit alleges that marketing executives at Schering-Plough, one of the makers of Vytorin, knew long before it was released that the ENHANCE study...
Vytorin Makers Spent Millions on Medical Education
Sep 15, 2009
| Parker Waichman LLP
Merck & Co. and Schering-Plough, the makers of Vytorin, spent millions over the past four years to educate doctors about the latest...
No Proof Combo Pills Like Vytorin Work Better, Study Finds
Sep 3, 2009
| Parker Waichman LLP
A new study says there is no proof that combo cholesterol lowering drugs like Vytorin work better than high doses of statins. Vytorin,...
Vytorin Makers Announce $41.5 Million Class Action Settlement
Aug 6, 2009
| Parker Waichman LLP
The makers of Vytorin are settling more lawsuits. According to a Reuters report, Merck and Schering-Plough will pay $41.5 million to settle...
Vytorin Named in Another Lawsuit
Jun 9, 2009
| Parker Waichman LLP
Vytorin, the controversial cholesterol-lowering drug, has been named in yet another lawsuit. According to Bloomberg.com, the Pennsylvania...
Vytorin Forum Postings Can Stay In Lawsuit, Judge Says
Jun 3, 2009
| Parker Waichman LLP
A judge in a Vytorin lawsuit has decided that some incriminating comments on an internet website frequented by pharmaceutical sales reps can be...
Vytorin Probe Seeks More Information
Feb 20, 2009
| Parker Waichman LLP
Lawmakers investigating the cholesterol drug Vytorin have asked Merck and Schering-Plough for more information on the medication's clinical...
Vytorin Named in 100+ Lawsuits, Justice Department Investigation
Dec 2, 2008
| Parker Waichman LLP
Nearly a year after an important Vytorin study raised serious doubts about its effectiveness, Merck and Schering-Plough are facing an increasing...
Experts Divided on Vytorin Cancer Risk
Nov 13, 2008
| Parker Waichman LLP
Vytorin was the subject of a heated debate at the annual meeting of the American Heart Association in New Orleans yesterday. At issue was the...
